Boston Scientific Corporation Announces Major Board Changes and \$4 Billion Increase to Stock Repurchase Authorization

Key Points for Investors

• Appointment of Two New Board Members: Boston Scientific Corporation has elected Cathy Smith and Christophe Weber to its Board of Directors.
• Large Increase in Stock Buyback Program: The Board has approved a significant \$4 billion increase to the company’s stock repurchase authorization, bringing the total authorized amount to \$5 billion.
• Potential Price Sensitivity: The expanded share repurchase program could provide strong support for the company’s share price and signals confidence in the company’s financial position and future prospects.

Details of the Board Appointments

On February 23, 2026, Boston Scientific Corporation (NYSE: BSX) announced the appointments of Cathy Smith and Christophe Weber to its Board of Directors.

The company clarified that neither Ms. Smith nor Mr. Weber were appointed pursuant to any arrangement or understanding with any other person, and neither has any material interest in any transaction that would require disclosure. These appointments are expected to add significant strategic and operational expertise to the Board, potentially strengthening the company’s governance and future direction.

Stock Repurchase Program Expansion

In a move likely to be welcomed by shareholders, Boston Scientific’s Board of Directors approved a substantial increase of \$4.0 billion to its existing share repurchase authorization on February 18, 2026. This brings the total amount authorized for repurchases to \$5.0 billion of the company’s common stock (par value \$0.01 per share), all of which remains available for repurchases as of the announcement date.

This expanded buyback authorization underscores management’s confidence in the company’s long-term growth strategy and its ability to generate robust cash flows. Large share repurchases can be a powerful mechanism for returning value to shareholders, potentially boosting earnings per share and supporting the share price, especially in volatile or uncertain market conditions.

Further Information

The company issued a press release on February 23, 2026, announcing these developments. The press release is available as Exhibit 99.1 in the SEC filing and provides additional background on the appointments and the company’s strategic direction.

Boston Scientific’s common stock trades on the New York Stock Exchange under the symbol BSX. The company also has 0.625% Senior Notes due 2027 trading under the symbol BSX27.

Why This News Matters to Shareholders

• Board appointments often bring renewed focus and direction to publicly traded companies. The addition of Ms. Smith and Mr. Weber may influence future strategic decisions and corporate governance.
• Stock buyback expansions are typically viewed favorably by investors. They can signal that the company’s leadership believes the shares are undervalued, and they can have a direct positive impact on share price by reducing the number of shares outstanding.
• Shareholder Value: The combination of new board expertise and a major commitment to buybacks may increase investor confidence and support the company’s market valuation.

About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve patient health worldwide. With over 45 years of leadership in medical technology, the company provides a broad range of high-performance solutions that address unmet patient needs and help reduce healthcare costs. Boston Scientific’s portfolio covers cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions.
Learn more at www.bostonscientific.com.

Contact Information

Media Relations:
Chanel Hastings
+1 (508) 382-0288
[email protected]

Investor Relations:
Lauren Tengler
+1 (508) 683-4479
[email protected]

Disclaimer: This article is based on publicly available information from Boston Scientific Corporation’s Form 8-K filing dated February 23, 2026. It is intended for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a qualified financial advisor before making any investment decisions.

View BOSTON SCIENTIFIC CORP Historical chart here